a unique solution for severe asthma dr talker olga pulmonary department
Download
Skip this Video
Download Presentation
A unique solution for severe asthma. Dr Talker Olga Pulmonary department

Loading in 2 Seconds...

play fullscreen
1 / 40

A unique solution for severe asthma. Dr Talker Olga Pulmonary department - PowerPoint PPT Presentation


  • 129 Views
  • Uploaded on

A unique solution for severe asthma. Dr Talker Olga Pulmonary department. C ase Presentation, 10.2009: . 48 year old lady, teacher at school Married +7 s/p op. d/t scoliosis at age 17 No smoking history Family history of severe asthma Allergy to dust mites

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' A unique solution for severe asthma. Dr Talker Olga Pulmonary department' - quiana


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
c ase presentation 10 2009
Case Presentation, 10.2009:

48 year old lady, teacher at school

Married +7

s/p op. d/t scoliosis at age 17

No smoking history

Family history of severe asthma

Allergy to dust mites

Severe asthma with recurrent exacerbations, recurrent prolonged courses of oral steroids, prednisone 30-40 mg.

a case 10 2009
A case, 10.2009:

BMI- 23

Normal CXR, normal ECHO, p-ANCA, c-ANCA- normal

High eosinophil count-1100

Stool examination- no parasites

PFT- obstructive pattern with FEV1- 60%

Treatment- Prednisone, Seretide 500, Foradil, Flixonase, Omepradex.

severe asthma definition
Severe asthma, definition:

Severe asthma- disease that requires high dose inhaled or near continuous oral glucocorticoid treatment to maintain asthma control.

to be excluded
To be excluded:

Ongoing exposure to triggers

Nonadherence

Alternative disorder that mimics asthma

Comorbidities

to be excluded1
To be excluded:

Ongoing exposure to triggers:

allergens, irritants at patient’s home, school, work-laboratory animals, latex, glutaraldehide, toluene diisocyanate, flour, NSAID’s, beta-blockers.

Adherence

to be excluded2
To be excluded:

Conditions that mimic asthma:

Vocal cord dysfunction( combination of inspiratory flow volume loop and laryngoscopy during symptoms), vocal cord paralysis, vocal cord lesions.

Central airway obstruction- tracheal strictures, tracheal copmpression by goiter, thracheal and proximal bronchial tumors, vascular rings( CT, bronchoscopy)

COPD- greater than 20 p.y. smoking history, family history of emphysema or alpha-1 antitrypsin deficiency, irreversible airflow obstruction and low diffusing capacity.

to be excluded3
To be excluded:

Bronchiectasis- copious productive cough, refractory to bronchodilator therapy, HRCT.

ABPA may develop patients with asthma d/t colonization of the airways with aspergillus and typically present with recurrent mucoid impaction and atelectasis, proximal bronchiectasis, skin test positive to aspergillus, elevated IgE (>1000 ng/ml).

Hypersensitivity pneumonitis- exposure to allergens- birds, barns, humidifiers, PFT- mixed obstructive and restrictive pattern, reduced DLCO, fleeting infiltrates.

to be excluded4
To be excluded:

Eosinophilia and respiratory sypmtoms: filariasis, trichinellosis, strongiloides infection- patients from endemic area, blood eosinophilia, elevated IgE, specific IgG to parasites, improvement with specific treatment.

Paranasal sinus disease, skin lesions, peripheral neuropathy, eosynophilia > 10% is common in Churg-Strauss s-me, p-ANCA positive.

Chronic eosinophilic pneumonia- fever, weight loss, night sweats, pulmonary infiltrates.

Endobronchialsarcoidosis- hylaradenopathy and interstitial opacities.

Cardiac disease- echocardiography.

to be excluded5
To be excluded:

Comorbidities:

Chronic rhinosinusitis, allergic rhinitis

GERD

Ongoing smoking

Obesity

OSA

Anxiety , depression.

a case 01 2010
A case, 01.2010:

IgE- 80 u/ml

Started Xolair- monoclonal anti-IgE antibody, 225 mg every two weeks

Prednisone tapering down

a case 11 2010
A case, 11.2010:

Receiving Xolair 225 mg every two weeks

Stopped Seretide

No prednisone

PFT- FEV1- 75%

the ige mediated inflammatory response type i hypersensitivity reaction
The IgE-mediated inflammatory response:type I hypersensitivity reaction

IgE

FceRI

B-cell

Allergen

Mast cell

Histamine

Leukotrienes

Prostaglandins

Cytokines

Atopic

disease

IL-4

IL-13

Th2-cell

IL-5

Antigen-presenting

cell

Eosinophil

Holgate ST. QJM 1998

xolair omalizumab prevents ige interacting with fc e ri on all cell types
Xolair® (omalizumab)prevents IgE interacting with FceRI on all cell types

IgE

Eosinophil

Macrophage/monocyte

Mast cell

Basophil

Dendritic cell

omalizumab ige complexes
Omalizumab:IgE Complexes
  • Omalizumab:IgE complexes are either trimers or hexamers, based on Xolair IgE ratio
  • The complexes are of limited size and are eliminated via the reticuloendothelial system
  • No specific organ accumulation, no bigger complexes

Omalizumab (~150 kD)

IgE (~190 kD)

Hexamer

(~1000 kD)

Trimers

(~490 kD- 530 kD)

reduction in serum free ige following s c administration of xolair
Reduction in serum free IgE following s.c. administration of Xolair®

Median free IgE (ng/mL)

300

  • 300mg administered once monthly for 48 weeks topatients with moderate-to-severe asthma

200

Day 1 post-dose

100

0

0

1

3

7

14

112

168

252

336

Days (not to scale)

Day 0 = screening (n=93)

Source: Extension Study Report 8C

innovate in vestigatio n of o malizumab in se v ere a sthma t r e atment
INNOVATEINvestigatioN of Omalizumab in seVereAsthma TrEatment

Humbert M, et al. Allergy 2005

  • Patients (aged 12–75 years) with allergic asthma
    • FEV1 40–<80% at randomization
    • Asthma symptoms in the 4 weeks prior to randomization despite high-dose ICS and LABA
    • Clinically meaningful exacerbations in the previous year:
      • Either 2 exacerbations requiring systemic steroids
      • Or a severe exacerbation (PEF or FEV1 <60% personal best) requiring systemic steroids and ER treatment
      • Or hospitalization
innovate results

Omalizumab

Placebo

* P = 0.04, ** P = 0.002, *** P = 0.038

INNOVATE Results

26 %

50 %

44.2 %

qol significantly improved overall and across all domains compared with placebo
QoL significantly improved overall and across all domains compared with placebo

Omalizumab

AQLQ score†

Placebo

0.95

**

0.91

***

0.90

***

0.91

***

1.0

0.8

0.6

0.4

0.2

0

0.89

***

Activities Emotions Symptoms Environment Overall

**p<0.01; ***p<0.001

†Change from baseline (least squares mean)

AQLQ = Asthma Quality of Life Questionnaire

omalizumab was well tolerated
Omalizumab was well tolerated
  • The percentage of patients who experienced adverse events (AEs) was similar in both treatment groups
    • omalizumab, 72.2%; placebo, 75.5%
  • Fewer serious AEs in the omalizumab group
    • omalizumab, 11.8%; placebo, 15.6%
  • AEs were generally mild or moderate in nature and of short duration

Humbert M, et al. Allergy 2005

gina 2007 guidelines anti ige therapy at step 5
GINA 2007 guidelines* anti-IgE therapy at step 5

*For children older than 5 years, adolescents and adults†Receptor antagonist or synthesis inhibitor

ICS = inhaled corticosteroid; LABA = long-acting β2-agonist

GINA Workshop Report 2007

summary of dosing strategy for xolair
Summary of dosing strategy for Xolair®
  • Free IgE target ~25ng/mL(10.4 IU/mL)
  • At least 0.016 mg / kg / IU IgE / month
  • Target Xolair®:IgE ratio greater than 15:1
  • Dose to be adjusted for individual’s baseline IgE and body weight
  • Dosing strategy accommodates a wide range of baseline IgE and body weights
omalizumab in severe allergic asthma real life experience meir medical center
Omalizumab in Severe Allergic Asthma: Real Life Experience Meir Medical Center
  • 54 patients
  • 47 patients fulfilled the selection criteria (at least 3 months of treatment)
  • Age: 61± 12 years (26-85)
  • Mean Ig E total levels: 281 ± 236 IU/ml
omalizumab in severe allergic asthma real life experience meir medical center1
Omalizumab in Severe Allergic Asthma: Real Life ExperienceMeir medical center
  • Duration of disease: 25 ±17 years (2-60)
  • Mean monthly Xolair dosage:

401± 241mg(150-1200).

  • Mean time on Xolair: 28± 18 months
lung functions
Lung functions

P=0.002

58.1±13.9

steroids reduction
Steroids reduction
  • 4 (8.5%) stopped steroids.
  • 10 (21%) reduced the dosage.
side effects
Side effects
  • Only 1 patient withdrawn
  • 5 patients with musculoskeletal pains.
  • No cardiovascular side effects.
  • No anaphylaxis.
  • No malignancies.
conclusions
CONCLUSIONS

Omalizumab is effective add-on treatment in patients with moderate to severe allergic asthma and accompany by an acceptable safety profile.

ad